Therapix Biosciences Ltd.
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
September 3, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| RE: | Therapix Biosciences Ltd. (CIK 0001611746) | |
| Registration Statement No. 333-233417 on Form F-3 (the “Registration Statement”) |
Ladies and Gentlemen:
Therapix Biosciences Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on September 5, 2019 at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
| Very truly yours, | ||
| Therapix Biosciences LTD. | ||
| By: | /s/ Ascher Shmulewitz | |
Ascher Shmulewitz, M.D, Ph.D. Chairman and Interim Chief Executive Officer | ||
